We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
UK Vaccine Taskforce Chairwoman Kate Bingham revealed Wednesday that the country will have millions fewer doses of AstraZeneca’s vaccine candidate available by the end of the year than previously anticipated. Read More
The Coalition for Epidemic Preparedness Innovations (CEPI) has agreed to fund development of a potential COVID-19 vaccine from China’s Clover Biopharmaceuticals with a global phase 2/3 study and through licensing and distribution. Read More
German biopharma company CureVac announced yesterday that its COVID-19 vaccine hopeful generated immune responses and was generally well-tolerated in phase 1 trial participants, lending support for a pivotal trial before year’s end. Read More
The researchers hope to determine whether the drug improves blood oxygen levels and reduces mortality as well as time spent in an intensive care unit. Read More
Despite announcing positive results for its phase 2/3 COVID-19 antibody cocktail trial Thursday, a potential safety signal has led Regeneron to temporarily stop enrolling patients who require high-flow oxygen or mechanical ventilation. Read More
Data from Regeneron’s phase 2/3 trial of its COVID-19 antibody cocktail showed the treatment significantly reduced viral load and the number of medical visits needed by nonhospitalized patients, the company said Thursday. Read More
Moderna is still on track to file for Emergency Use Authorization (EUA) for its COVID-19 vaccine in the later part of November and is currently gearing up for worldwide distribution. Read More